A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Trial Profile

A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Interleukin-2 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2017.
    • 09 Oct 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top